Access this Article

Abstract

KRAS遺伝子変異を持ったがんを標的とした新規のアルキル化剤の開発について. 京都大学プレスリリース. 2015-05-01.

Despite extensive efforts to target mutated RAS proteins, anticancer agents capable of selectively killing tumour cells harbouring KRAS mutations have remained unavailable. Here we demonstrate the direct targeting of KRAS mutant DNA using a synthetic alkylating agent (pyrrole-imidazole polyamide indole-seco-CBI conjugate; KR12) that selectively recognizes oncogenic codon 12 KRAS mutations. KR12 alkylates adenine N3 at the target sequence, causing strand cleavage and growth suppression in human colon cancer cells with G12D or G12V mutations, thus inducing senescence and apoptosis. In xenograft models, KR12 infusions induce significant tumour growth suppression, with low host toxicity in KRAS-mutated but not wild-type tumours. This newly developed approach may be applicable to the targeting of other mutant driver oncogenes in human tumours.

Journal

  • Nature Communications

    Nature Communications (6), 2015-04-27

    Springer Nature

Codes

  • NII Article ID (NAID)
    120006460100
  • Text Lang
    ENG
  • Article Type
    journal article
  • ISSN
    2041-1723
  • Data Source
    IR 
Page Top